Oric Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 71
Rang # Quantité totale PI 19 137
Note d'activité PI 2,8/5.0    84
Rang # Activité PI 8 334
Symbole boursier ORIC (nasdaq)
ISIN US68622P1093
Capitalisation 698M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

27 2
6 2
32 0
2
 
Dernier brevet 2025 - Treatment of refractory multiple...
Premier brevet 2016 - Inhibitors of glucocorticoid rec...
Dernière marque 2023 - ORIC
Première marque 2021 - ORIC

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Treatment of refractory multiple myeloma. The present disclosure relates to methods of treating a...
Invention Cd73 inhibitor and anti-cd38 agent combination therapy. The present disclosure relates to methods...
Invention Prc2 inhibitors for use in treating sickle cell disease. The present disclosure relates to method...
Invention Treatment of prostate cancer. The present disclosure relates to methods of treating prostate canc...
Invention Cd73 inhibitors. Described herein are CD73 inhibitors and pharmaceutical compositions comprising...
Invention Egfr inhibitor for treating cancers comprising atypical egfr mutations. The present application p...
Invention Treatment of t-cell lymphoma. Disclosed herein are methods of treating T-cell lymphoma in a subje...
Invention Treatment of neuroendocrine prostate cancer. Disclosed herein are methods of treating neuroendocr...
2023 Invention Treatment of prostate cancer having androgen receptor variants. Disclosed herein are methods of t...
Invention Malonate and glycolate salts of an egfr inhibitor. The present application provides salts and cry...
Invention Polo like kinase 4 inhibitors. Disclosed herein are compounds of Formula (IV), or pharmaceuticall...
Invention Pharmaceutical forms of a cd73 inhibitor
Invention Physical forms of an inhibitor of prc2
Invention Physical forms of an inhibitor of prc2. The present disclosure relates to physical forms of a PRC...
Invention Pharmaceutical forms of a cd73 inhibitor. The present disclosure relates to pharmaceutical forms ...
Invention Polo like kinase 4 inhibitors. Disclosed herein are compounds of Formula (I), or pharmaceutically...
P/S Pharmaceutical preparations for use in the treatment of cancer, tumors, and hematological maligna...
2022 Invention Cd73 inhibitors. Described herein are CD73 inhibitors and pharmaceutical compositions comprising ...
Invention Inhibitors of epidermal growth factor receptor. Disclosed herein are compounds of Formula (I), o...
Invention Inhibitors of epidermal growth factor receptor. Disclosed herein are compounds of Formula (I), or...
Invention Prc2 inhibitors for use in treating blood disorders. The present disclosure relates to methods o...
Invention Prc2 inhibitors for use in treating blood disorders. The present disclosure relates to methods of...
Invention Inhibitors of glucocorticoid receptor. The present invention relates generally to compositions a...
P/S pharmaceutical preparations for use in the treatment of cancer, tumors, and hematological maligna...
Invention Polo like kinase 4 inhibitors. Disclosed herein are compounds of Formula (I), or pharmaceuticall...
Invention Uses of glucocorticoid receptor (gr) antagonist, antiandrogen, and akt inhibitor/pi3k inhibitor/m...
2021 Invention Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations....
P/S drugs for addressing medical conditions, namely, medicinal preparations for treating cancers or t...
Invention Glucocorticoid receptor gene signature. The present invention relates generally to the use of a p...
P/S Pharmaceutical preparations and substances; pharmaceutical preparations for use in the treatment ...
P/S Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea...
Invention Uses of glucocorticoid receptor antagonists. The present invention relates generally to the use o...
2020 Invention Cd73 inhibitors. Described herein are CD73 inhibitors and pharmaceutical compositions compr...
2019 Invention Glucocorticoid receptor modulators. Described herein are glucocorticoid receptor modulators and ...
Invention Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof. T...
2016 Invention Inhibitors of glucocorticoid receptor. The present invention relates generally to compositions an...